Remove 2003 Remove Disease Remove Packaging Remove Vaccine
article thumbnail

CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis

The Pharma Data

It causes inflammation in the kidneys and can lead to end-stage kidney disease which may require dialysis or a transplant. 2] LN can lead to end-stage kidney disease, which requires kidney dialysis or a transplant. Approximately 20% of patients with LN progress to end-stage kidney disease within 10 years of diagnosis. [5].

article thumbnail

European Commission approves Benlysta for adult patients with active lupus nephritis

The Pharma Data

Benlysta is the first biologic approved to treat lupus and lupus nephritis, representing a significant new treatment option for patients and physicians across Europe dealing with this complex autoimmune disease.”. 2] LN can lead to end-stage kidney disease, which could require dialysis or a kidney transplant.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

When the document was taken back to the drawing board again in 2003, it remained on hold for more than a decade until a final version was agreed upon in 2012, with the FDA officially adopting it in 2014. While the SRP could be used to submit information on drugs and biological products, the only exception was for vaccines.

FDA 40
article thumbnail

A Texas Mess

Drug & Device Law

The complaint, brought under the Texas consumer protection statute, sued a major manufacturer of COVID-19 vaccine that was used to control the recent pandemic. To the contrary, the COVID-19 vaccine in question was fully approved by the FDA as safe and effective on August 23, 2021, and has remained so (or updated versions have) ever since.

Vaccine 59